9 stories mentioning PTCTUpdated 11d ago
Every FINWIRES story that references PTCT, newest first.
Eric Pauwels, Chief Business Officer, on June 10, 2026, sold 21,277 shares in PTC Therapeutics (PTCT) for $1,595,775. Following the Form 4 filing with the SEC, Pauwels has control over a total of 73,411 common shares of the company, with 73,411 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1070081/000132321226000010/xslF345X05/form4-06122026_050610.xml
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.6% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.2%.The iShares Biotechnology ETF (IBB) added 1.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 1%, and Nuvalent surged 39%.Brookdale Senior Living (BKD) has reported May occupancy data in line with bullish comments by the company's management at a recent event and ahead of levels implied in RBC's model for Q2, RBC Capital Markets said in a note. Brookdale shares jumped past 8%.PTC Therapeutics (PTCT) shares climbed 3.3% after Citigroup upgraded the company's stock to buy and raised its price target to $108.Eli Lilly (LLY) signed a collaboration and licensing deal worth over $1 billion with AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.4%.
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.4%.The iShares Biotechnology ETF (IBB) added 1.2%.In corporate news, PTC Therapeutics (PTCT) shares climbed 4.1% after Citigroup upgraded the company's stock to buy and raised its price target to $108.
PTC Therapeutics (PTCT) shares were up about 3.5% in Tuesday trading after Citigroup upgraded the company's stock to buy and raised its price target to $108.Trading volume stood at nearly 1.1 million shares compared with a daily average of roughly 1.2 million.Price: $73.44, Change: $+2.57, Percent Change: +3.63%
PTC Therapeutics (PTCT) has an average rating of overweight and mean price target of $91.57, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each shedding about 0.9%. The iShares Biotechnology ETF (IBB) decreased 0.3%.In sector news, President Donald Trump has approved a plan to fire the US Food and Drug Administration Commissioner Marty Makary, the Wall Street Journal reported Friday. Trump expressed displeasure in recent days with Makary for taking too long to approve flavored vapes and nicotine pouches, the Journal reported earlier this week.In corporate news, Zoetis (ZTS) shares fell past 5% after Ameriprise downgraded the stock to hold from buy following its Q1 results Thursday. UBS also cut its price target to $99 from $130, and Jefferies to $117 from $155.Traws Pharma (TRAW) shares surged 28%. The company said Friday it plans to develop potential therapies for the treatment and prevention of hantavirus infections using its portfolio of antiviral drug candidates targeting negative-strand RNA viruses.Novo Nordisk (NVO) saw a 40% month-on-month surge in April sales of its diabetes and weight-loss drugs in India after slashing prices, despite a flood of generic versions, Bloomberg reported, citing data from market researcher Pharmarack. Novo added 0.5%.PTC Therapeutics (PTCT) shares jumped past 14% after posting a smaller-than-expected net loss for Q1, as well as total revenue that surpassed analysts' consensus.
Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each shedding 0.9%.The iShares Biotechnology ETF (IBB) decreased 0.3%.In corporate news, PTC Therapeutics (PTCT) shares jumped past 14% after posting a smaller-than-expected net loss for Q1, as well as total revenue that surpassed analysts' consensus.
(Updates with recent stock movement in headline and first paragraph.)PTC Therapeutics (PTCT) shares rose 17% in afternoon trading on Friday after posting a lower-than-expected net loss for Q1, as well as total revenue that surpassed analysts' consensus.The company reported late Thursday a Q1 net loss of $0.03 per diluted share, swinging from earnings of $10.04 a year earlier.Analysts polled by FactSet expected a loss of $0.47.Total revenue for the three months ended March 31 fell to $272.6 million from $1.18 billion a year earlier.Analysts surveyed by FactSet expected $218.8 million.For 2026, the company expects total revenue of $1.08 billion to $1.18 billion. Analysts expect $982.9 million.Price: $75.91, Change: $+11.42, Percent Change: +17.70%
PTC Therapeutics (PTCT) has an average rating of overweight and mean price target of $90.43, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
